Phase I and pharmacokinetic study of once-daily dosing of intravenously administered busulfan in the setting of a reduced-intensity preparative regimen and allogeneic hematopoietic stem cell transplantation as immunotherapy for renal cell carcinoma

Military Medicine

Volumn 171, Issue 2, 2006, Pages 161-165

  Shaughnessy, Paul ^a   Alexander, Warren ^b   Tran, Hai ^c   Ririe, David ^b   Splichal, James ^b   Pollack, Marilyn ^d   Bachier, Carlos ^a   LeMaistre, Charles ^a  

^a TEXAS TRANSPLANT INSTITUTE   (United States)

^b WILFORD HALL MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; COTRIMOXAZOLE; CYCLOSPORIN; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; METHOTREXATE; PENTAMIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APHERESIS; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG DOSE REGIMEN; DRUG HALF LIFE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; IMMUNOTHERAPY; KIDNEY ARTERY EMBOLIZATION; KIDNEY CARCINOMA; KIDNEY FAILURE; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; NAUSEA; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PNEUMOCYSTOSIS; SIBLING; SOMNOLENCE; SURVIVAL TIME; UNINEPHRECTOMY; VEIN OCCLUSION; VIREMIA; VOMITING;

EID: 32144433537     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.7205/MILMED.171.2.161     Document Type: Article

References (21)

1. Tutschka PJ, Copelan EA, Klein JP: Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-8.
2. Clift RA, Buckner CD, Thomas ED, et al: Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-43.
3. Schuler U, Schroer S, Kuhnle A, Schmidt H, Ehninger G: Busulfan pharmacokinetics in BMT patients: is drug monitoring warranted? Bone Marrow Transplant 1994; 14: 759-65.
4. Slattery JT, Sanders JE, Buckner CD, et al: Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31-42.
5. Slattery JT, Clift RA, Buckner CD. et al: Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89: 3055-60.
6. Andersson BS, Bhagwatwar H, Chow D: Parenteral busulfan for treatment of malignant disease. U.S. patents 5,430,057 and 5,55.148. 1995 and 1996.
7. Bhagwatwar HP, Phadungpojna S, Chow DS, Andersson BS: Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharamcol 1996; 37: 401-8.
8. Andersson BS. Madden T, Tran HT. et al: Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pre-transplantation conditioning therapy: a Phase 1 study. Biol Blood Marrow Transplant 2000; 6: 548-54.
9. Shaughnessy PJ, Omstein D, Ririe D. et al: Phase II study of a moderate-intensity preparative regimen with allogeneic peripheral blood stem cell transplantation for hematologic diseases: the Texas Transplant Consortium experience. Biol Blood Marrow Transplant 2002; 8: 420-8.
10. Childs R, Chemoff A, Contentin N, et al: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-8.
11. Childs R: Nonmyeloabaltive blood stem cell transplantation as adoptive allogeneic immunotherapy for metastatic renal cell carcinoma. Crit Rev Immunol 2001; 21: 191-203.
12. Tran HT, Madden T, Petropoulos D, et al: Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant 2000; 26: 463-70.
13. D'Argenio DZ, Schumitzky A: A program package for simulation and parameter estimation in pharmacokinetics. Comput Programs Biomed 1979; 9: 115-34.
14. Glucksberg H, Storb R, Fefer A, et al: Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
15. Bearman SI: The syndrome of hepatic veno-occusive disease after marrow transplantation. Blood 1995; 85: 3005-20.
16. Bornhauser M, Thiede C, Schuler U, et al: Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant 2000; 26: 119-25.
17. Fernandez H, Tran HT, Albrecht F, et al: Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 486-92.
18. Russell JA, Tran HT, Quinlan C, et al: Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468-76.
19. Phadungpojna S, Chow DS-L, Reardan DT, Champlin RE, Andersson BS: Pharmacokinetics and toxicity of parenteral busulfan in dogs [abstract]. Proc Am Assoc Cancer Res 1996; 37: 2528.
20. Lichtman SM, Etcubanas E, Budman DR et al: The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study. Cancer Invest 2002; 20: 904-13.
21. Nelson RP, Logan TF, Abonour R: Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma. Bone Marrow Transplant 2002; 30: 805-12.